Kite Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

 

• Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment
• Data Builds on Previous Evidence on the Association Between Timely Infusion and Patient Outcomes
• Preliminary Results Supporting Safety and Feasibility of Outpatient Administration of Yescarta and Tecartus^® to be Presented

https://www.biospace.com/article/releases/new-kite-clinical-research-and-real-world-evidence-for-yescarta-demonstrate-benefit-from-earlier-lines-of-treatment/